Cory Abate-Shen

Cory Abate-Shen

Titles

Michael and Stella Chernow Professor of Urological Oncology

Affiliations

Department of Pathology and Cell Biology
Department of Systems Biology
Center for Cancer Systems Therapeutics

Administrative Coordinator:
Rachel Kelly
rjk2135@cumc.columbia.edu


Cory Abate-Shen is a professor in the Department of Urology and Department of Pathology and Cell Biology, the Michael and Stella Chernow Chair of Urological Oncology, and an associate director of the Herbert Irving Cancer Center. She is investigating the molecular mechanisms of homeobox genes in development and cancer. Her laboratory has provided groundbreaking insights on the molecular bases of how homeoproteins achieve target gene recognition in vivo. She has also developed mouse models of prostate cancer that have been widely used to investigate the molecular bases of prostate tumorigenesis and as preclinical models for intervention and therapy. She has been the recipient of several awards, including a Sinsheimer Scholar Award, an NSF Young Investigator Award, and the Women in Cell Biology Junior Award from the American Society for Cell Biology. She is currently the principal investigator on five federal grants including an NCI consortium grant on Mouse Models of Human Cancer. In addition, she has received funding from several other sources including the March of Dimes, the New Jersey Commission on Cancer Research and the Gustave and Louise Pfeiffer Research Foundation. She has recently been named an American Association of Cancer Research Professor.

More News

News

Dr. Cory Abate-Shen Elected an AAAS Fellow
The American Association for the Advancement of Science has elected Dr. Cory Abate-Shen a 2018 Fellow, recognizing her work in the development of innovative mouse models to better understand how basic cellular mechanisms are co-opted in cancer and for her contributions to the field of cancer biology. A leader in genitourinary malignancies, Dr. Abate-Shen is particularly interested in advancing our understanding of the mechanisms and modeling of prostate and bladder tumors. She holds joint appointments in the Departments of Systems Biology, Medicine and Pathology & Cell Biology.
Columbia Team Awarded New Prostate Cancer Grant for Innovative Precision Cancer Research
The Prostate Cancer Foundation (PCF) has announced more than $5.5 million in research funding to six new 2018 PCF Challenge Award teams, including an interdisciplinary team at Columbia University Irving Medical Center. The Columbia team includes Systems Biology faculty Drs. Michael Shen, Andrea Califano and Cory Abate-Shen, with several leading investigators from the Herbert Irving Comprehensive Cancer Center, the James J. Peters Veterans Affairs Medical Center and Dana-Farber Cancer Institute.
Michael Shen Wins Cancer Research Innovation Award
The Bladder Cancer Advocacy Network has awarded Professor Michael Shen, PhD, the 2018 Bladder Cancer Research Innovation Award. The honor singles out scientists whose creative, novel research has great potential to advance therapies for bladder cancer, the fifth most common cancer in the U.S.
Columbia Joins Global Consortium to Advance Precision Cancer Medicine
Columbia University has joined Project GENIE, which brings together leading institutions in cancer research and treatment to provide a repository for the largest possible amount of clinical-grade cancer genomic data and clinical outcomes data. At Columbia, GENIE is being led by Drs. Raul Rabadan of systems biology and Richard Carvajal of medicine.
Columbia Awarded NCI Center for Cancer Systems Biology
The Center for Cancer Systems Therapeutics (CaST) is developing a framework that can account for the dynamic nature of cancer and use this knowledge to disrupt the programs that maintain tumor survival.